{
  "source": "PA-Notification-Tasigna.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1105-14\nProgram Prior Authorization/Notification\nMedication Tasigna® (nilotinib)\nP&T Approval Date 8/2008, 6/2009, 9/2010, 12/2010, 9/2011, 8/2012, 07/2013, 2/2014,\n2/2015, 2/2016, 12/2016, 11/2017, 11/2018, 11/2019, 11/2020,\n11/2021, 11/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nTasigna® (nilotinib) is a kinase inhibitor indicated for the treatment of adult and pediatric\npatients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome\npositive chronic myeloid leukemia (Ph+ CML) in chronic phase, as well as treatment of adult\npatients with chronic phase (CP) and accelerated phase Ph+ CML resistant to or intolerant to\nprior therapy that included Gleevec® (imatinib).1 Tasigna is also indicated for treatment of\npediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP\nresistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. The National Cancer\nComprehensive Network (NCCN) recommends the use of Tasigna for primary or follow-up\nCML therapy in all stages. NCCN also recommends Tasigna for the treatment of the following:\nprogressive gastrointestinal stromal tumors (GIST) when patient is no longer receiving benefit\nfrom Gleevec® (imatinib), Stivarga® (regorafenib), Qinlock® (ripretinib), or Sutent® (sunitinib);\nfor the treatment of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (B-\nALL); in cutaneous melanoma with activating mutations of KIT and/or projected risk of\nprogression with BRAF-targeted therapy; for the treatment of soft tissue sarcoma of pigmented\nvillonodular synovitis/tenosynovial giant cell tumor; and for myeloid/lymphoid neoplasms with\neosinophilia and tyrosine kinase fusion genes. 2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage revie",
    "s. 2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Tasigna will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n1\nB. Chronic Myeloid Leukemia\n1. Initial Authorization\na. Tasigna will be approved based on the following criterion:\n(1) Diagnosis of chronic myeloid leukemia\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tasigna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tasigna therapy\nAuthorization will be issued for 12 months.\nC. Gastrointestinal Stromal Tumor (GIST)\n1. Initial Authorization\na. Tasigna will be approved based on both of the following criteria:\n(1) Diagnosis of progressive gastrointestinal stromal tumor (GIST)\n-AND-\n(2) History of failure, contraindication, or intolerance to all of the following:\n(a) Gleevec (imatinib)\n(b) Sutent (sunitinib)\n(c) Stivarga (regorafenib)\n(c) Qinlock (ripretinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tasigna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tasigna therapy\nAuthorization will be issued for 12 months.\nD. Acute Lymphoblastic Leukemia (Ph+B-ALL)\n1. Initial Authorization\na. Tasigna will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n2\n(1) Diagnosis of Philadelphia chromosome",
    "mphoblastic Leukemia (Ph+B-ALL)\n1. Initial Authorization\na. Tasigna will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n2\n(1) Diagnosis of Philadelphia chromosome-positive B-cell acute lymphoblastic\nleukemia (Ph+ B-ALL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tasigna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tasigna therapy\nAuthorization will be issued for 12 months.\nE. Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes\n1. Initial Authorization\na. Tasigna will be approved based on the following criteria:\n(1) Diagnosis of myeloid, lymphoid or mixed lineage neoplasms with eosinophilia\nand ABL1 rearrangement\n-AND-\n(2) Neoplasm is in blast or chronic phase\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tasigna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tasigna therapy\nAuthorization will be issued for 12 months.\nF. Melanoma: Cutaneous\n1. Initial Authorization\na. Tasigna will be approved based on both of the following criteria:\n(1) Diagnosis of metastatic or unresectable melanoma cutaneous tumors with\nactivating mutations of KIT\n-AND-\n(2) Used as second-line or subsequent therapy for disease progression, intolerance,\nand or projected risk of progression with BRAF-targeted therapy\n© 2024 UnitedHealthcare Services, Inc.\n3\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tasigna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tasigna therapy\nAuthorization will be issued for 12 months.\nG. Soft Tissue Sarcoma\n1. Initial Authorization\na. Tasigna will be approved based on the following criterion:\n(1) Diagnosis of pigmented villonodular synovitis/tenosynovial giant cell tumor\nAuthorization will be issued for 12 months.\n2. Reauthorization\n",
    "signa will be approved based on the following criterion:\n(1) Diagnosis of pigmented villonodular synovitis/tenosynovial giant cell tumor\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tasigna will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tasigna therapy\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n4\n4. References:\n1. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nFebruary 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nOctober 3, 2024.\nProgram Prior Authorization/Notification - Tasigna (nilotinib)\nChange Control\n2/2014 Updated references.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual review. Added Stivarga as t/f option for GIST. Expanded\nPh+ALL criteria to include genetic mutations or transplant. Updated\nbackground and references.\n2/2016 Annual review with clinical updates based on NCCN recommendations\nwhich expand",
    " for GIST. Expanded\nPh+ALL criteria to include genetic mutations or transplant. Updated\nbackground and references.\n2/2016 Annual review with clinical updates based on NCCN recommendations\nwhich expanded coverage for all CML diagnoses. Updated background\nand references.\n12/2016 Annual review. No changes to criteria intent. Updated background and\nreferences.\n11/2017 Annual review. Updated background information and coverage criteria\nto include NCCN recommended use for Ph+ ALL. Removed acute\nlymphoblastic lymphoma criteria as no longer recommended by NCCN.\nUpdated references.\n11/2018 Annual review. Minor change to coverage rationale for CML with no\nchange in clinical intent. Removed “off-label” from NCCN\nCompendium supported indications. Updated background and\nreferences.\n11/2019 Annual review. Updated coverage criteria for GIST, added NCCN\nrecommended regimens criteria. Updated references.\n11/2020 Annual review. Addition of coverage criteria for myeloid/lymphoid\nneoplasms with eosinophilia and ABL1 rearrangement according to\nNCCN. Updated background and references.\n11/2021 Annual review. Clarified B-cell type ALL in coverage criteria. Updated\nbackground and references.\n11/2022 Annual review. Added state mandate. Updated background per package\ninsert and references.\n11/2023 Annual review. Updated criteria for GIST. Updated criteria for\nMyeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase\nGene Fusions. Added Melanoma Cutaneous and Soft Tissue Sarcoma as\nindications for criteria per NCCN recommendations. Updated\nbackground and reference.\n11/2024 Annual review with no changes to criteria. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}